Par Drugs & Chemicals Ltd

Par Drugs & Chemicals Management Change

Par Drugs re-appointed its statutory auditor and executive director/CEO. These appointments were approved at the company's 27th Annual General Meeting.

Par Drugs & Chemicals Annual General Meeting

Par Drugs and Chemicals Limited held its 27th Annual General Meeting on September 26, 2026. Management reviewed the company's financial performance and business affairs during the session.

Par Drugs & Chemicals Other Announcement

Par Drugs and Chemicals Limited is notifying shareholders about access to the FY 2025-26 Annual Report and 27th AGM notice via web-link.

Par Drugs & Chemicals Management Change

Par Drugs and Chemicals Limited has re-appointed M/s. Siddhpura & Co. as Internal Auditor and M/s. Maulin Shah & Associates as Cost Auditor.

Par Drugs & Chemicals Annual General Meeting

Par Drugs and Chemicals Limited has scheduled its 27th Annual General Meeting for September 26, 2026, in Vadodara to transact scheduled ordinary and special business.

Par Drugs & Chemicals Q4 FY26 Results: Net Profit ₹13.1 Cr, Down 2.2% YoY

Par Drugs & Chemicals Ltd reported revenue from operations of ₹103.7 Cr (+2.7% YoY) and net profit of ₹13.1 Cr (-2.2% YoY) for Q4 FY26.

Key figure

Net profit ₹13.1 Cr · -2.2% YoY

Par Drugs & Chemicals Board Meeting Date

Par Drugs and Chemicals Limited has scheduled a board meeting for August 22, 2026. The meeting will address other business matters.

Par Drugs & Chemicals Q1 FY27 Results: Net Profit ₹4.7 Cr, Up 42.4% YoY

Par Drugs & Chemicals Ltd reported revenue from operations of ₹31.3 Cr (+20.4% YoY) and net profit of ₹4.7 Cr (+42.4% YoY) for Q1 FY27.

Key figure

Net profit ₹4.7 Cr · +42.4% YoY